OBJECTIVES: Guidelines recommend that sepsis be treated with an early resuscitation protocol such as early goal-directed therapy. Our objective was to assess the cost-effectiveness of implementing early goal-directed therapy as a routine protocol. DESIGN: Prospective before and after study. SETTING: Large urban hospital emergency department with >110,000 visits/yr. PATIENTS: The target population was patients with consensus criteria for septic shock. We excluded those with age <18 yrs, no aggressive care desired, or need for immediate surgery. INTERVENTIONS: Clinical and cost data were prospectively collected on two groups: 1) patients from 1 yr before; and 2) 2 yrs after implementing early goal-directed therapy as standard of care. Before phase patients received nonprotocolized care at attending discretion. The primary outcomes were 1-yr mortality, discounted life expectancy, and quality-adjusted life-years. Using costs and quality-adjusted life-years, we constructed an incremental cost-effectiveness ratio and performed a net monetary benefit analysis, producing the probability that the intervention was cost-effective given different values for the willingness to pay for a quality-adjusted life-year. RESULTS: Two hundred eighty-five subjects, 79 in the before and 206 in the after phases, were enrolled. Treatment with early goal-directed therapy was associated with an increased hospital cost of $7,028 and an increase in both discounted sepsis-adjusted life expectancy and quality-adjusted life years of 1.5 and 1.3 yrs, respectively. Early goal-directed therapy use was associated with a cost of $5,397 per quality-adjusted life-years gained and the net monetary benefit analysis indicates a 98% probability (p = .038) that early goal-directed therapy is cost-effective at a willingness to pay of $50,000 per quality-adjusted life-years. CONCLUSION: Implementation of early goal-directed therapy in the emergency department care of patients with severe sepsis is cost-effective.
OBJECTIVES: Guidelines recommend that sepsis be treated with an early resuscitation protocol such as early goal-directed therapy. Our objective was to assess the cost-effectiveness of implementing early goal-directed therapy as a routine protocol. DESIGN: Prospective before and after study. SETTING: Large urban hospital emergency department with >110,000 visits/yr. PATIENTS: The target population was patients with consensus criteria for septic shock. We excluded those with age <18 yrs, no aggressive care desired, or need for immediate surgery. INTERVENTIONS: Clinical and cost data were prospectively collected on two groups: 1) patients from 1 yr before; and 2) 2 yrs after implementing early goal-directed therapy as standard of care. Before phase patients received nonprotocolized care at attending discretion. The primary outcomes were 1-yr mortality, discounted life expectancy, and quality-adjusted life-years. Using costs and quality-adjusted life-years, we constructed an incremental cost-effectiveness ratio and performed a net monetary benefit analysis, producing the probability that the intervention was cost-effective given different values for the willingness to pay for a quality-adjusted life-year. RESULTS: Two hundred eighty-five subjects, 79 in the before and 206 in the after phases, were enrolled. Treatment with early goal-directed therapy was associated with an increased hospital cost of $7,028 and an increase in both discounted sepsis-adjusted life expectancy and quality-adjusted life years of 1.5 and 1.3 yrs, respectively. Early goal-directed therapy use was associated with a cost of $5,397 per quality-adjusted life-years gained and the net monetary benefit analysis indicates a 98% probability (p = .038) that early goal-directed therapy is cost-effective at a willingness to pay of $50,000 per quality-adjusted life-years. CONCLUSION: Implementation of early goal-directed therapy in the emergency department care of patients with severe sepsis is cost-effective.
Authors: Nathan I Shapiro; Michael D Howell; Daniel Talmor; Dermot Lahey; Long Ngo; Jon Buras; Richard E Wolfe; J Woodrow Weiss; Alan Lisbon Journal: Crit Care Med Date: 2006-04 Impact factor: 7.598
Authors: Stephen Trzeciak; R Phillip Dellinger; Nicole L Abate; Robert M Cowan; Mary Stauss; J Hope Kilgannon; Sergio Zanotti; Joseph E Parrillo Journal: Chest Date: 2006-02 Impact factor: 9.410
Authors: Marcus J Schultz; Martin W Dunser; Arjen M Dondorp; Neill K J Adhikari; Shivakumar Iyer; Arthur Kwizera; Yoel Lubell; Alfred Papali; Luigi Pisani; Beth D Riviello; Derek C Angus; Luciano C Azevedo; Tim Baker; Janet V Diaz; Emir Festic; Rashan Haniffa; Randeep Jawa; Shevin T Jacob; Niranjan Kissoon; Rakesh Lodha; Ignacio Martin-Loeches; Ganbold Lundeg; David Misango; Mervyn Mer; Sanjib Mohanty; Srinivas Murthy; Ndidiamaka Musa; Jane Nakibuuka; Ary Serpa Neto; Mai Nguyen Thi Hoang; Binh Nguyen Thien; Rajyabardhan Pattnaik; Jason Phua; Jacobus Preller; Pedro Povoa; Suchitra Ranjit; Daniel Talmor; Jonarthan Thevanayagam; C Louise Thwaites Journal: Intensive Care Med Date: 2017-03-27 Impact factor: 17.440
Authors: Zhongheng Zhang; Yucai Hong; Nathan J Smischney; Han-Pin Kuo; Panagiotis Tsirigotis; Jordi Rello; Win Sen Kuan; Christian Jung; Chiara Robba; Fabio Silvio Taccone; Marc Leone; Herbert Spapen; David Grimaldi; Sven Van Poucke; Steven Q Simpson; Patrick M Honore; Stefan Hofer; Pietro Caironi Journal: J Thorac Dis Date: 2017-02 Impact factor: 2.895
Authors: Vempalli N Subramanyam; Nidhi Kaeley; Manish Kumar; Subodh K Pandey; Bharat B Bhardwaj; Konda S Reddy Journal: J Family Med Prim Care Date: 2020-05-31
Authors: Wesley H Self; Dandan Liu; Nicholas Strayer; Stephan Russ; Michael J Ward; Nathan I Shapiro; Todd W Rice; Matthew W Semler Journal: Chest Date: 2018-11-09 Impact factor: 9.410
Authors: Sudhagar Thangarasu; Piruthiviraj Natarajan; Parivalavan Rajavelu; Arjun Rajagopalan; Jeremy S Seelinger Devey Journal: Int J Emerg Med Date: 2011-09-05